Case: MiMedx Group, Inc.
Contact: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

February 20, 2018 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating MiMedx Group, Inc. (“MiMedx” or the “Company”) (NASDAQ: MDXG), a developer and marketer of regenerative and therapeutic biologics, concerning potential securities law violations.  Investors who purchased MiMedx shares may be affected.

On February 20, 2018, before the market opened, MiMedx issued a press release disclosing that its audit committee “has engaged independent legal and accounting advisors to conduct an internal investigation into current and prior-period matters relating to allegations regarding certain sales and distribution practices at the Company.”  The Company further advised investors that “Company executives are also reviewing, among other items, the accounting treatment of certain distributor contracts.”  In connection with these disclosures, MiMedx also announced that it is postponing the release of its financial results, as well as the filing of its Form 10-K, for the year ended December 31, 2017. 

On February 20, 2018, following the above disclosures, MiMedx’s shares plummeted $5.72 per share, or 39.5%, to close at $8.75 per share on heavy trading volume.

If you are an investor in MiMedx and would like to discuss our investigation, please contact us by emailing This e-mail address is being protected from spambots. You need JavaScript enabled to view it or by calling 800-290-1952.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Kaplan Fox & Kilsheimer LLP, with offices in New York, San Francisco, Los Angeles, Chicago and New Jersey, has many years of experience in prosecuting investor class actions. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com.  If you have any questions about this Notice, the action, your rights, or your interests, please contact: 

Donald R. Hall
KAPLAN FOX & KILSHEIMER LLP
850 Third Avenue, 14th Floor
New York, New York 10022
(800) 290-1952
(212) 687-1980
Fax: (212) 687-7714
E-mail: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
350 Sansome Street, Suite 400 
San Francisco, California  94104
(415) 772-4700
Fax:  (415) 772-4707
E-mail: This e-mail address is being protected from spambots. You need JavaScript enabled to view it